查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553444

肿瘤伴同性诊断市场规模、份额和趋势分析报告：按产品/服务、按技术、按产品类型、按疾病类型、按最终用途、按地区和细分市场预测，2024-2030 年

Oncology Companion Diagnostic Market Size, Share & Trends Analysis Report By Product & Service, By Technology (IHC, NGS), By Disease Type (Breast Cancer, Leukemia), By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

肿瘤伴同性诊断市场成长与趋势：

Grand View Research, Inc. Masu 的最新报告显示，到 2030 年，全球肿瘤伴同性诊断市场规模预计将达到 83.8 亿美元，2024 年至 2030 年复合年增长率为 8.7%。

全面的基因组测试和肿瘤学，随着伴同性诊断扩大了对关键基因组资讯的获取，使患者能够做出明智的决策和设计标靶治疗方法，对伴同性诊断的需求正在增加。

随着Gleevec/Glivec（Imatinib）和Herceptin（曲妥珠单抗）等需要在处方前进行伴同性诊断 (CDx) 测试的药物的推出，肿瘤伴同性诊断的销售额不断增加。由于临床试验中大量 CDx 相关癌症治疗药物，预计未来将持续下去。除了作为治疗的独家或综合测试外，CDx 在临床试验的参与者选择中也发挥着重要作用。如果患者有生物标记靶点，候选药物更有可能获得更高的反应率。

与伴随诊断相关的经济奖励鼓励药物开发商将药物与诊断测试结合。然而，诊断製造商一方面面临付款人/提供者的相互衝突的需求，另一方面面临药品製造商的相互矛盾的需求。此外，监管机构有严格的政策来协调诊断和药物开发时间表。因此，诊断製造商预计将扩大伴随诊断的开发范围，而不是专注于将单一诊断与特定药物相匹配。

肿瘤伴同性诊断市场报告亮点

  • 2023年肌肉骨骼义肢装置的市场占有率将超过42.8.0%，其次是视觉人工电子耳。同时，由于渗透率不断上升以及产品创新研发力度加大，视网膜神经修復术已被确定为成长最快的细分市场之一。
  • 由于脊髓刺激（SCS）疗法具有镇痛特性，用于治疗缺血性疼痛、背部手术失败综合征和复杂难治性疼痛综合征，因此脊髓刺激（SCS）节段所占份额最大，超过49.2% 。此外，它也被应用于透过椎管内和硬膜外微刺激来诱导腿部运动。此外，该领域的技术进步预计将在不久的将来进一步推动市场成长。由于荐椎神经刺激（SNS）在慢性顽固性骨盆疼痛和神经源性膀胱方面的应用，预计将成为预测期内成长最快的领域。
  • 就应用领域而言，由于帕金森氏症和癫痫的增加，运动神经元疾病占据了最大的部分。例如，根据帕金森氏症基金会2012年发布的报告，每年约有6万名美国被诊断出患有帕金森氏症，预计这一数字在预测期内将进一步增加，随着这一细分市场的成长正在蓬勃发展。
  • 2023年，北美占整个神经修復市场的42.5%以上。这是由于神经植入製造商数量众多、研发投资高以及政府和私人机构提供的资金充足。例如，国防高级研究计划局 (DARPA) 和国家神经病变和中风研究所 (NIH) 与联邦机构合作，提供资金支持进一步开发神经植入的研究和开发倡议。
  • 由于跨国医疗保健的引入以及意识层级不断提高，亚太地区预计将成为成长最快的产业。
  • 策略联盟和併购预计将在预测期内保持行业的高竞争水平。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章肿瘤伴同性诊断市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 肿瘤伴同性诊断市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章肿瘤伴同性诊断市场：产品与服务评估及趋势分析

  • 全球肿瘤伴同性诊断市场：产品与服务仪表板
  • 全球肿瘤伴同性诊断市场：产品与服务变化分析
  • 全球肿瘤伴同性诊断市场：按产品/服务分類的收益
  • 产品
  • 服务

第五章肿瘤伴同性诊断市场：技术评估与趋势分析

  • 全球肿瘤伴同性诊断市场：技术仪表板
  • 全球肿瘤伴同性诊断市场：技术变迁分析
  • 全球肿瘤伴同性诊断市场：按技术分類的收益
  • 聚合酵素链锁反应(PCR)
  • 次世代定序（NGS）
  • 免疫组织化学 (IHC)
  • 原位杂交（ISH）/萤光原位杂交（FISH）
  • 其他技术

第六章肿瘤伴同性诊断市场：疾病类型估计与趋势分析

  • 全球肿瘤伴同性诊断市场：疾病类型仪表板
  • 全球肿瘤伴同性诊断市场：疾病类型变异分析
  • 全球肿瘤伴同性诊断市场：按疾病类型分類的收益
  • 乳癌
  • 非小细胞肺癌
  • 大肠直肠癌
  • 白血病
  • 恶性黑色素瘤
  • 摄护腺癌
  • 其他的

第七章肿瘤伴同性诊断市场：最终用途估计与趋势分析

  • 全球肿瘤伴同性诊断市场：最终用途仪表板
  • 全球肿瘤伴同性诊断市场：最终用途变异分析
  • 全球肿瘤伴同性诊断市场：依最终用途分類的收益
  • 医院
  • 病理/诊断实验室
  • 学术医疗中心

第八章肿瘤伴同性诊断市场：区域估计与趋势分析

  • 区域仪表板
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第9章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2023年主要企业市场占有率分析
    • Agilent Technologies, Inc.
    • Illumina, Inc.
    • QIAGEN
    • Thermo Fisher Scientific Inc.
    • Foundation Medicine, Inc.
    • Myriad Genetics, Inc.
    • F. Hoffmann-La Roche Ltd.
    • BioMerieux
    • Abbott
    • Leica Biosystems
    • Guardant Health, Inc.
    • EntroGen, Inc.
Product Code: GVR-4-68039-049-7

Oncology Companion Diagnostic Market Growth & Trends:

The global oncology companion diagnostic market size is expected to reach USD 8.38 billion by 2030, expanding at a CAGR of 8.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Expanding access to important genomic information with the aid of companion diagnostics enables informed decision making for designing the targeted treatment approaches for their patients, thereby increasing demand for comprehensive genomic testing and oncology companion diagnostics.

The commercial launch of drugs including Gleevec (imatinib) and Herceptin (trastuzumab) that require Companion Diagnostics (CDx) testing before prescription has increased revenue generation in the oncology companion diagnostics field. This growth is expected to continue in the future owing to a substantial number of CDx associated oncology drugs in clinical trials. Apart from functioning as exclusive or inclusive tests for therapies, CDx also plays a crucial role during participant selection in clinical trials. This is because there is an increased potential for a novel drug candidate to show a better response rate if the patient has its biomarker target.

The economic incentives associated with the use of CDx have encouraged drug developers to combine their drugs with diagnostic tests. However, the diagnostic manufacturers face conflicting demands from payers/providers on one hand and drug manufacturers on the other hand. The regulatory bodies also have stringent policies to align the development timelines of diagnostics and drugs. Therefore, the diagnostic companies are expected to broaden their scope of CDx development instead of focusing on the attainment of a match between a single diagnostic with a specific drug.

Oncology Companion Diagnostic Market Report Highlights:

  • The motor prosthetic devices segment dominated in terms of revenue share and accounted for over 42.8.0% of the market in 2023, followed by visual cochlear implants. Whereas, retinal neuroprosthetics were identified as one of the fastest growing market segment owing to the rising penetration and the increasing R&D efforts pertaining to product innovation.
  • The Spinal Cord Stimulation (SCS) segment held the largest share at over 49.2% owing to the analgesic property of the SCS therapy used in the treatment of ischemic pain, failed back surgery syndrome, and complex refractory pain syndrome. Furthermore, it finds applications in intraspinal and epidural microstimulation for inducing leg movements. In addition, technological advancements in this segment is expected to further boost market growth in the near future. The sacral Nerve Stimulation (SNS) is expected to be the fastest growing segment over the forecast period due to its applications in chronic intractable pelvic ache and neurogenic bladder.
  • In the applications segment, motor neuron disorders held the largest segment due to the rising incidences of Parkinson's disease and epilepsy. For instance, as per the report published by Parkinson's disease Foundation in 2012, approximately 60,000 Americans were diagnosed with Parkinson's disease each year and the number is expected to grow further over the forecast period thereby fueling this segment's growth.
  • In 2023, North America dominated the overall neuroprosthetics market at over 42.5% owing to the large presence of neural implants manufacturers, higher R&D investments, and the availability of funds from both government and private institutes. For instance, the Defense Advanced Research Project Agency (DARPA) and National Institute of Neurological Disorders and Stroke (NIH)in collaboration with the federal agencies are instrumental in providing funds to support R&D initiatives for the further development of neural implants.
  • Asia Pacific is anticipated to be the fastest growing segment due to the introduction of multinational healthcare establishments promoting safe and effective medical procedures along with the rising awareness levels amongst consumers.
  • Strategic collaborations and mergers & acquisitions are expected to keep the industry rivalry level high over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product & Services
    • 1.2.2. Technology
    • 1.2.3. Disease Type
    • 1.2.4. End-use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product & services and technology outlook
    • 2.2.2. Disease type and end-use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Oncology Companion Diagnostic Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of cancer
      • 3.2.1.2. Growing adoption of companion diagnostics
      • 3.2.1.3. Rising emphasis on personalized medicine
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Complex regulatory landscape
      • 3.2.2.2. Limited awareness and adoption in developing countries
  • 3.3. Oncology Companion Diagnostic Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Oncology Companion Diagnostic Market: Product & Services Estimates & Trend Analysis

  • 4.1. Global Oncology Companion Diagnostic Market: Product & Services Dashboard
  • 4.2. Global Oncology Companion Diagnostic Market: Product& Services Movement Analysis
  • 4.3. Global Oncology Companion Diagnostic Market by Product& Services, Revenue
  • 4.4. Product
    • 4.4.1. Product market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Instruments
      • 4.4.2.1. Product market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Consumables
      • 4.4.3.1. Consumables market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Software
      • 4.4.4.1. Software market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Services
    • 4.5.1. Services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Oncology Companion Diagnostic Market: Technology Estimates & Trend Analysis

  • 5.1. Global Oncology Companion Diagnostic Market: Technology Dashboard
  • 5.2. Global Oncology Companion Diagnostic Market: Technology Movement Analysis
  • 5.3. Global Oncology Companion Diagnostic Market by Technology, Revenue
  • 5.4. Polymerase Chain Reaction (PCR)
    • 5.4.1. Polymerase Chain Reaction (PCR) market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Next-generation Sequencing (NGS)
    • 5.5.1. Next-generation Sequencing (NGS) market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Immunohistochemistry (IHC)
    • 5.6.1. Immunohistochemistry (IHC) market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH)
    • 5.7.1. In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH) market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Other Technologies
    • 5.8.1. Other technologies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Oncology Companion Diagnostic Market: Disease Type Estimates & Trend Analysis

  • 6.1. Global Oncology Companion Diagnostic Market: Disease Type Dashboard
  • 6.2. Global Oncology Companion Diagnostic Market: Disease Type Movement Analysis
  • 6.3. Global Oncology Companion Diagnostic Market by Disease Type, Revenue
  • 6.4. Breast Cancer
    • 6.4.1. Breast cancer market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Non-small Cell Lung Cancer
    • 6.5.1. Non-small cell lung cancer market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Colorectal Cancer
    • 6.6.1. Colorectal cancer market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Leukemia
    • 6.7.1. Leukemia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Melanoma
    • 6.8.1. Melanoma market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. Prostate Cancer
    • 6.9.1. Prostate cancer market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.10. Others
    • 6.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Oncology Companion Diagnostic Market: End-use Estimates & Trend Analysis

  • 7.1. Global Oncology Companion Diagnostic Market: End-use Dashboard
  • 7.2. Global Oncology Companion Diagnostic Market: End-use Movement Analysis
  • 7.3. Global Oncology Companion Diagnostic Market by End-use, Revenue
  • 7.4. Hospitals
    • 7.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Pathology/Diagnostic Laboratory
    • 7.5.1. Pathology/Diagnostic laboratory market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Academic Medical Center
    • 7.6.1. Academic medical center market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Oncology Companion Diagnostic Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2023
    • 9.3.4. Agilent Technologies, Inc.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Illumina, Inc.
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. QIAGEN
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Thermo Fisher Scientific Inc.
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Foundation Medicine, Inc.
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Myriad Genetics, Inc.
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. F. Hoffmann-La Roche Ltd.
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. BioMerieux
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Abbott
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Leica Biosystems
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. Guardant Health, Inc.
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Product benchmarking
      • 9.3.14.4. Strategic initiatives
    • 9.3.15. EntroGen, Inc.
      • 9.3.15.1. Company overview
      • 9.3.15.2. Financial performance
      • 9.3.15.3. Product benchmarking
      • 9.3.15.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 4 Global Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 5 Global Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 6 Global Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 7 Global Oncology Companion Diagnostic, by Region, 2018 - 2030 (USD Million)
  • Table 8 North America Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Million)
  • Table 9 North America Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 10 North America Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 11 North America Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 12 North America Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 13 U.S. Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 14 U.S. Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 15 U.S. Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 16 U.S. Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 17 Canada Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 18 Canada Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 19 Canada Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 20 Canada Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 21 Mexico Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 22 Mexico Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 23 Mexico Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 24 Mexico Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 25 Europe Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Million)
  • Table 26 Europe Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 27 Europe Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 28 Europe Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 29 Europe Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 30 Germany Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 31 Germany Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 32 Germany Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 33 Germany Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 34 UK Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 35 UK Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 36 UK Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 37 UK Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 38 France Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 39 France Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 40 France Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 41 France Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 42 Italy Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 43 Italy Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 44 Italy Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 45 Italy Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 46 Spain Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 47 Spain Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 48 Spain Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 49 Spain Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 50 Denmark Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 51 Denmark Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 52 Denmark Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 53 Denmark Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 54 Sweden Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 55 Sweden Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 56 Sweden Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 57 Sweden Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 58 Norway Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 59 Norway Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 60 Norway Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 61 Norway Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 67 China Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 68 China Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 69 China Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 70 China Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 71 Japan Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 72 Japan Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 73 Japan Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 74 Japan Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 75 India Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 76 India Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 77 India Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 78 India Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 79 South Korea Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 80 South Korea Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 81 South Korea Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 82 South Korea Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 83 Australia Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 84 Australia Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 85 Australia Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 86 Australia Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 87 Thailand Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 88 Thailand Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 89 Thailand Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 90 Thailand Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 91 Latin America Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Million)
  • Table 92 Latin America Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 93 Latin America Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 94 Latin America Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 95 Latin America Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 96 Brazil Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 97 Brazil Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 98 Brazil Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 99 Brazil Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 100 Argentina Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 101 Argentina Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 102 Argentina Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 103 Argentina Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 108 Middle East & Africa Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 109 South Africa Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 110 South Africa Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 111 South Africa Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 112 South Africa Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 116 Saudi Arabia Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 117 UAE Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 118 UAE Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 119 UAE Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 120 UAE Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
  • Table 123 Kuwait Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
  • Table 124 Kuwait Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Oncology Companion Diagnostic Market Segmentation
  • Fig. 8 Market Snapshot, 2023
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 Global Oncology Companion Diagnostic Market: Product & Services Movement Analysis
  • Fig. 16 Global Oncology Companion Diagnostic Market, for Product, 2018 - 2030 (USD Million)
  • Fig. 17 Global Oncology Companion Diagnostic Market, for Services, 2018 - 2030 (USD Million)
  • Fig. 18 Global Oncology Companion Diagnostic Market: Technology Movement Analysis
  • Fig. 19 Global Oncology Companion Diagnostic Market, for Polymerase Chain Reaction (PCR), 2018 - 2030 (USD Million)
  • Fig. 20 Global Oncology Companion Diagnostic Market, for Next-generation Sequencing (NGS), 2018 - 2030 (USD Million)
  • Fig. 21 Global Oncology Companion Diagnostic Market, for Immunohistochemistry (IHC), 2018 - 2030 (USD Million)
  • Fig. 22 Global Oncology Companion Diagnostic Market, for In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH), 2018 - 2030 (USD Million)
  • Fig. 23 Global Oncology Companion Diagnostic Market, for Other Technologies, 2018 - 2030 (USD Million)
  • Fig. 24 Global Oncology Companion Diagnostic Market: Disease Type Movement Analysis
  • Fig. 25 Global Oncology Companion Diagnostic Market, for Breast Cancer, 2018 - 2030 (USD Million)
  • Fig. 26 Global Oncology Companion Diagnostic Market, for Non-small Cell Lung Cancer, 2018 - 2030 (USD Million)
  • Fig. 27 Global Oncology Companion Diagnostic Market, for Colorectal Cancer, 2018 - 2030 (USD Million)
  • Fig. 28 Global Oncology Companion Diagnostic Market, for Leukemia, 2018 - 2030 (USD Million)
  • Fig. 29 Global Oncology Companion Diagnostic Market, for Melanoma, 2018 - 2030 (USD Million)
  • Fig. 30 Global Oncology Companion Diagnostic Market, for Prostate Cancer, 2018 - 2030 (USD Million)
  • Fig. 31 Global Oncology Companion Diagnostic Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 32 Global Oncology Companion Diagnostic Market: End-use Movement Analysis
  • Fig. 33 Global Oncology Companion Diagnostic Market, for Hospitals, 2018 - 2030 (USD Million)
  • Fig. 34 Global Oncology Companion Diagnostic Market, for Pathology/Diagnostic Laboratory, 2018 - 2030 (USD Million)
  • Fig. 35 Global Oncology Companion Diagnostic Market, for Academic Medical Center, 2018 - 2030 (USD Million)
  • Fig. 36 Regional Marketplace: Key Takeaways
  • Fig. 37 Regional Outlook, 2023 & 2030
  • Fig. 38 Global Oncology Companion Diagnostic Market: Region Movement Analysis
  • Fig. 39 North America Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 41 Canada Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 42 Mexico Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 43 Europe Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 44 Germany Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 45 UK Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 46 France Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 47 Italy Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 48 Spain Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 49 Denmark Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 50 Sweden Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 51 Norway Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 52 Asia Pacific Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 53 Japan Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 54 China Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 55 India Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 56 Australia Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 57 South Korea Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 58 Thailand Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 59 Latin America Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 60 Brazil Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 61 Argentina Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 62 Middle East and Africa Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 63 South Africa Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 64 Saudi Arabia Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 65 UAE Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
  • Fig. 66 Kuwait Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)